ATE480568T1 - Verbesserte sgp 130fc dimere - Google Patents

Verbesserte sgp 130fc dimere

Info

Publication number
ATE480568T1
ATE480568T1 AT06013668T AT06013668T ATE480568T1 AT E480568 T1 ATE480568 T1 AT E480568T1 AT 06013668 T AT06013668 T AT 06013668T AT 06013668 T AT06013668 T AT 06013668T AT E480568 T1 ATE480568 T1 AT E480568T1
Authority
AT
Austria
Prior art keywords
dimere
sgp
improved
dimer
molecules
Prior art date
Application number
AT06013668T
Other languages
English (en)
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Application granted granted Critical
Publication of ATE480568T1 publication Critical patent/ATE480568T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06013668T 2006-06-30 2006-06-30 Verbesserte sgp 130fc dimere ATE480568T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013668A EP1873166B1 (de) 2006-06-30 2006-06-30 Verbesserte sgp 130Fc Dimere

Publications (1)

Publication Number Publication Date
ATE480568T1 true ATE480568T1 (de) 2010-09-15

Family

ID=37654867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06013668T ATE480568T1 (de) 2006-06-30 2006-06-30 Verbesserte sgp 130fc dimere

Country Status (21)

Country Link
US (3) US8895012B2 (de)
EP (1) EP1873166B1 (de)
JP (1) JP5417171B2 (de)
KR (1) KR101474817B1 (de)
CN (1) CN101484472B (de)
AT (1) ATE480568T1 (de)
AU (1) AU2007263939B2 (de)
BR (1) BRPI0713063B8 (de)
CA (1) CA2656440C (de)
CY (1) CY1110973T1 (de)
DE (1) DE602006016765D1 (de)
DK (1) DK1873166T3 (de)
EA (1) EA015620B1 (de)
ES (1) ES2352561T3 (de)
HR (1) HRP20100663T1 (de)
PL (1) PL1873166T3 (de)
PT (1) PT1873166E (de)
RS (1) RS51544B (de)
SI (1) SI1873166T1 (de)
UA (1) UA95636C2 (de)
WO (1) WO2008000516A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
EP2050759A1 (de) * 2007-10-19 2009-04-22 CONARIS research institute AG Lösliche gp-130-Muteine mit verbesserter Bindungsaktivität
EP3851459B1 (de) * 2010-09-21 2024-05-01 Altor BioScience, LLC Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN105474718B (zh) * 2013-09-20 2019-09-20 英特尔公司 Ap位置查询
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
MX2017007067A (es) 2014-12-01 2018-04-30 Ferring Bv Administracion de un inhibidor selectivo de la trans-señalizacion de il-6.
MD3227325T2 (ro) * 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
EP3529263B1 (de) 2016-10-21 2025-08-06 Altor BioScience Corporation Multimere auf il-15-basierende moleküle
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
WO2020006469A1 (en) * 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating and reducing traumatic brain injury-associated impairments using sgp130
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115867345A (zh) * 2020-06-10 2023-03-28 辉凌有限公司 用于治疗动脉粥样硬化性心血管疾病的药物化合物
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
US20240359144A1 (en) * 2021-09-01 2024-10-31 Telix Pharmaceuticals (Innovations) Pty Ltd Aggregate separation method
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis
EP4570816A1 (de) 2023-12-14 2025-06-18 Consejo Superior De Investigaciones Científicas - CSIC Lösliches gp130fc (sgp130fc) zur verwendung in der behandlung von sars-cov-2

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
PL199659B1 (pl) * 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
ATE382636T1 (de) * 2000-04-21 2008-01-15 Conaris Res Inst Ag Fusionsproteine, die zwei lösliche gp130 moleküle enthalten
HUP0400442A2 (hu) * 2001-05-21 2005-03-29 Nektar Therapeutics Kémiailag módosított inzulin pulmonáris beadása és eljárás az előállítására
EP1406929A2 (de) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusionproteine
WO2003024389A2 (en) * 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
CN1802167A (zh) * 2003-06-12 2006-07-12 伊莱利利公司 融合蛋白质
EP1491554A1 (de) 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1630232B1 (de) 2004-08-27 2008-07-02 CONARIS research institute AG Optimierte Nukleotidsequenzen die für sgp130 kodieren
EP1801121A1 (de) 2005-12-23 2007-06-27 CONARIS research institute AG Lösliche Varianten des Moleküls gp130 nützlich als Arzneimittel
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere

Also Published As

Publication number Publication date
US9573989B2 (en) 2017-02-21
WO2008000516A3 (en) 2008-03-27
EP1873166A1 (de) 2008-01-02
BRPI0713063B8 (pt) 2021-05-25
RS51544B (sr) 2011-06-30
BRPI0713063B1 (pt) 2019-10-08
KR101474817B1 (ko) 2014-12-22
CA2656440C (en) 2018-10-02
AU2007263939A1 (en) 2008-01-03
EA200802396A1 (ru) 2009-06-30
CN101484472B (zh) 2013-07-24
EP1873166B1 (de) 2010-09-08
KR20090037898A (ko) 2009-04-16
CY1110973T1 (el) 2015-06-11
US20100028367A1 (en) 2010-02-04
AU2007263939B2 (en) 2011-11-24
DE602006016765D1 (de) 2010-10-21
WO2008000516B1 (en) 2008-05-08
PT1873166E (pt) 2010-12-09
US9034817B2 (en) 2015-05-19
CN101484472A (zh) 2009-07-15
ES2352561T3 (es) 2011-02-21
EA015620B1 (ru) 2011-10-31
BRPI0713063A2 (pt) 2012-04-17
HRP20100663T1 (hr) 2011-01-31
JP5417171B2 (ja) 2014-02-12
WO2008000516A2 (en) 2008-01-03
SI1873166T1 (sl) 2011-01-31
PL1873166T3 (pl) 2011-03-31
UA95636C2 (en) 2011-08-25
US8895012B2 (en) 2014-11-25
CA2656440A1 (en) 2008-01-03
JP2009540843A (ja) 2009-11-26
US20150361157A1 (en) 2015-12-17
DK1873166T3 (da) 2010-12-20
US20140178378A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CY1110973T1 (el) Βελτιωμενα διμερη sgp130fc
NZ592509A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
UY31123A1 (es) Proteinas de fusion natriureticas
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
ATE294817T1 (de) Concatamere immunadhäsion
AR072596A1 (es) Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
BRPI0514052A (pt) proteìnas de fusão rage e métodos de utilização
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
DE602008005596D1 (de) Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
BRPI0720879B8 (pt) microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação
ATE346095T1 (de) Glycoprotein vi - fc fusions protein zur behandlung von gefässerkrankungen
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
WO2012078761A3 (en) Dimeric molecular complexes with free cysteine residues and conjugates thereof
MX2022008748A (es) Administración oral de péptidos.
EA200600561A1 (ru) Фармацевтический препарат для лечения шока
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt
EA200800205A1 (ru) Кальций-пептидный компонент

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1873166

Country of ref document: EP